Deal Watch: Teva and Celltrion Announce Biosimilar Commercial Partnership

Teva Pharmaceutical Industries Ltd., Celltrion, Inc. and Celltrion Healthcare announced that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s biosimilar candidates: CT-P10, a proposed mAb biosimilar to Rituxan (rituximab), and CT-P6, a proposed mAb biosimilar to Herceptin (trastuzumab).

Stay tuned to the Big Molecule Watch for further developments.

 

Download PDF